TrialDisease markers2019

Favorable Response to CD34+ Cell Therapy Is Associated with a Decrease of Galectin-3 Levels in Patients with Chronic Heart Failure.

Gregor Poglajen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.